Literature DB >> 17177671

Do skin prick and conjunctival provocation tests predict symptom severity in seasonal allergic rhinoconjunctivitis?

Michael J Radcliffe1, George T Lewith, Philip Prescott, Martin K Church, Stephen T Holgate.   

Abstract

BACKGROUND: In the investigation of seasonal allergic rhinoconjunctivitis (SAR), quantitative skin and conjunctival allergen challenge tests are used to measure individual allergen sensitivity. These tests are reproducible and relate well to prevalence but their relationship to symptom severity is less well established.
OBJECTIVE: We wished to determine if quantitative skin prick tests (QSPT) and conjunctival provocation tests (CPTs) using a single grass pollen allergen extract are reproducible and predict symptom severity in SAR.
METHODS: We retrospectively analysed data from 91 participants in a previously published randomized placebo controlled study of low dosage allergen immunotherapy who were randomized to receive placebo treatment. We examined the relationship between pre-seasonal QSPT, CPT and SAR symptoms.
RESULTS: We found a high level of reproducibility when repeated measures were compared for both the QSPT (P < 0.001) and the CPT (P < 0.001) and moderate correlation (0.49) between the standard skin prick test (SPT) and the QSPT (P < 0.001). We found weak negative correlation (-0.27) between the QSPT and the CPT (P < 0.001). We found no correlation between seasonal symptom, use of rescue medication or quality of life (QOL) scores and pre-seasonal QSPT or CPT. Conclusion In the assessment of seasonal rhinoconjunctivitis, quantitative skin and conjunctival allergen challenge tests are strongly reproducible, although there is no correlation between these tests and seasonal symptom, use of rescue medication or QOL scores.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17177671     DOI: 10.1111/j.1365-2222.2006.02594.x

Source DB:  PubMed          Journal:  Clin Exp Allergy        ISSN: 0954-7894            Impact factor:   5.018


  10 in total

Review 1.  Allergic rhinitis: an updated overview.

Authors:  Sverre K Steinsvaag
Journal:  Curr Allergy Asthma Rep       Date:  2012-04       Impact factor: 4.806

2.  Increased IL-5 and IL-13 cytokine level in ex vivo stimulated whole blood cells from grass pollen allergic donors correlate with seasonal exposure.

Authors:  Anurag Singh; Sébastien Holvoet; Marietta Weiss; Maurice Beaumont; Adrian W Zuercher; Annick Mercenier
Journal:  Results Immunol       Date:  2011-07-27

3.  Allergic conjunctivitis and nasal allergy.

Authors:  Zdenek Pelikan
Journal:  Curr Allergy Asthma Rep       Date:  2010-07       Impact factor: 4.806

4.  Is there any correlation between the results of skin-prick test and the severity of symptoms in allergic rhinitis?

Authors:  Emel Cadallı Tatar; Unzile Akpınar Sürenoğlu; Güleser Saylam; Eray Işık; Ali Ozdek; Hakan Korkmaz
Journal:  Am J Rhinol Allergy       Date:  2012 Jan-Feb       Impact factor: 2.467

Review 5.  Climate change, aeroallergens, and pediatric allergic disease.

Authors:  Perry E Sheffield; Kate R Weinberger; Patrick L Kinney
Journal:  Mt Sinai J Med       Date:  2011 Jan-Feb

6.  Basophil activation test compared to skin prick test and fluorescence enzyme immunoassay for aeroallergen-specific Immunoglobulin-E.

Authors:  Faisal M Khan; Aito Ueno-Yamanouchi; Bazir Serushago; Tom Bowen; Andrew W Lyon; Cathy Lu; Jan Storek
Journal:  Allergy Asthma Clin Immunol       Date:  2012-01-20       Impact factor: 3.406

7.  Potential bias in ophthalmic pharmaceutical clinical trials.

Authors:  Paul Varner
Journal:  Clin Ophthalmol       Date:  2008-06

8.  Strong dose response after immunotherapy with PQ grass using conjunctival provocation testing.

Authors:  S Zielen; P Kuna; W Aberer; S Lassmann; O Pfaar; L Klimek; A Wade; K Kluehr; J Raab; D Wessiepe; D Lee; M F Kramer; K Gunawardena; T Higenbottam; M D Heath; M A Skinner; P J de Kam
Journal:  World Allergy Organ J       Date:  2019-10-25       Impact factor: 4.084

9.  Randomized controlled trials define shape of dose response for Pollinex Quattro Birch allergoid immunotherapy.

Authors:  M Worm; T Higenbottam; O Pfaar; R Mösges; W Aberer; K Gunawardena; D Wessiepe; D Lee; M F Kramer; M Skinner; B Lees; S Zielen
Journal:  Allergy       Date:  2018-06-19       Impact factor: 13.146

10.  Early nonreactivity in the conjunctival provocation test predicts beneficial outcome of sublingual immunotherapy.

Authors:  Janina Köther; Alicia Mandl; Silke Allekotte; Anatoli Astvatsatourov; Janin Chwieralski; Jan-Patrick Liedtke; Ursula Pieper-Fürst; Esther Raskopf; Kija Shah-Hosseini; Ralph Mösges
Journal:  Clin Transl Allergy       Date:  2018-07-04       Impact factor: 5.871

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.